Company Deployed 15 Safe Entry Stations at Circuit of the Americas in Austin, Texas to Screen Hospitality Suite Attendees and Catering Staff
TORONTO, ON / ACCESSWIRE / October 25, 2021 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today announced the revenue-generating deployment of 15 Safe Entry Stations at the Formula 1 Aramco United States Grand Prix, which was held October 22-24, 2021 at the Circuit of The Americas ("COTA") in Austin, Texas, as part of the Company's reseller partnership with the Canadian-based JUICEWORKS EXHIBITS and CONNECTUS Global.
Predictmedix's proprietary AI-enabled screening solution was used for hospitality suite entrances and catering staff at the world's most prestigious motor racing competition and most popular annual sporting series. The race weekend was expected to draw over 100,000 attendees per day to experience racing action, musical, amusement rides and local cuisine.
Upon arrival, guests holding passes to enclosed hospitality areas and suites were asked to walk through the Predictmedix Safe Entry Station to rapidly identify multiple symptoms of infectious diseases associated with COVID-19, displaying the result in the form of a red or green light. Guests receiving a red light were to be asked to take a self-administered rapid antigen test.
Mike Anderson of CONNECTUS Global, a Predictmedix Safe Entry Station Reseller, commented, "We are excited to have worked with the COTA teams on their extended health and safety plans. The safety of patrons is the top priority of the organization and the steps they are taking to ensure a safe return to live events truly reenforces them as leaders in the industry."
"Live sporting and other large-scale events are quickly returning in popularity, and our onsite solution has become a product of choice for leading global facilities to ensure the safety of employees and guests in attendance," said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. "With each deployment of our stations, we gain further validation that only strengthens the conversion of our robust sales pipeline through our international network of resellers. We are truly privileged to launch our technology at this world-famous race, and provide a meaningful difference to the safety of its guests."
About Predictmedix Inc.
Predictmedix (CSE:PMED)(OTCQB:PMEDF) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, or various mental illnesses. Predictmedix's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Caution Regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
SOURCE: Predictmedix Inc.